Latest News

Pulmonary Deposition of BUD/Glycopyrrolate/Formoterol in COPD Patients


A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered dose inhaler in patients with moderate‑to‑very severe chronic obstructive pulmonary disease. Simbec-Orion worked with two leading organisations, Astra Zeneca and Cardiff Scintigraphics, to successfully complete a scintigraphy study in COPD patients. About the COPD study Study Title A scintigraphy study of budesonide/ glycopyrrolate/ formoterol fumarate metered […]

Read More

Fundraising for Findacure for Rare Disease Day 2021 


As a CRO specialising in clinical trials for rare and orphan diseases, Rare Disease Day has become a special cause to us. This year we wanted to give something back to the rare disease patient community and offer our employees the chance to get their families involved in some creative fundraising activities. Inspired by 2021’s […]

Read More

Read our latest article – Rare disease clinical trials continue, thanks to new technology


Rare Disease Day offers a valuable opportunity to raise awareness of rare disease and campaign for health equity. We are delighted to take part in Health Awareness’ Rare Diseases campaign this year, which in addition to our own contribution, features articles from Genetic Alliance UK, Rare Diseases International and EURORDIS to offer a diverse range […]

Read More

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks


We worked with KalVista Pharmaceuticals to study Oral KVD900 in Patients with Hereditary Angioedema (HAE) in this phase II clinical trial. Results included the observation that attacks treated with KVD900 significantly reduced use of rescue with 15% of KVD900 treated attacks rescued compared to 30% on placebo at 12 hours.

Read More

Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications


Vault CTMS and Vault eTMF provide complete visibility into trials, enabling CRO to deliver value-added services to sponsors PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE: VEEV) today announced that Simbec-Orion, a full-service contract research organization (CRO) specialized in clinical pharmacology, oncology, and rare diseases, is adopting Veeva Vault CTMS and Veeva Vault eTMF to digitize end-to-end clinical trial data, workflows, and documents. Veeva […]

Read More

Simbec-Orion and Oncodistinct Network agreement to strengthen early phase oncology research


Providing oncology drug developers with the successful delivery of early phase oncology studies. Slough, Berkshire, United Kingdom: Simbec-Orion announced a charter agreement between the Oncodistinct Network and Simbec-Orion. The agreement strengthens the relationships between Simbec-Orion and the Oncodistinct network of oncology sites, who partner in operations and scientific expertise in the design and conduct of […]

Read More

Exvastat wins a 3.6 million euro grant for COVID-19 trial


Congratulations to Cambridge Innovation Capital portfolio company Exvastat that has been awarded a grant from the prestigious Innovative Medicines Initiative. The grant will be used to reformulate and study imatinib in the treatment of Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) in collaboration with Vrije Universiteit Amsterdam (VU Amsterdam), KABS Laboratories Inc. and Simbec-Orion. Read […]

Read More

Got a question?
Get in Touch or Submit an RFI/RFP

Our team is on hand to answer any questions you might have relating to the work we do at Simbec-Orion. Just fill in the form below, making sure to tick the boxes that apply, and we’ll respond as quickly as we can.

Looking to volunteer for a clinical trial?

Visit our dedicated volunteer website here, or email

Follow us on Social Media

Opt In Emails